Gibson Dunn has advised RTW Investments, LP. RTW Investments, LP has acquired a synthetic royalty interest in Anaphylm™ (epinephrine) Sublingual Film from Aquestive Therapeutics, Inc. Additionally,...
RTW Investments Acquires Synthetic Royalty Interest in Anaphylm and Participates in Aquestive Therapeutics’ $85 Million Offering
Concentra Biosciences to Acquire iTeos Therapeutics in Cash and CVR Transaction
Gibson, Dunn & Crutcher LLP has advised Concentra Biosciences, LLC on the transaction, and Ropes & Gray LLP has advised iTeos Therapeutics, Inc. Concentra Biosciences, LLC...
XenoTherapeutics to Acquire ESSA Pharma in All-Cash Agreement Backed by XOMA Royalty
Skadden, Arps, Slate, Meagher & Flom LLP, alongside Blake, Cassels & Graydon LLP, have advised ESSA Pharma Inc. Stikeman Elliott LLP and Gibson, Dunn & Crutcher...
HealthCare Royalty and Blue Owl Capital Acquire BridgeBio Pharma’s BEYONTTRA Royalty Interest for $300 Million
Gibson Dunn has advised HealthCare Royalty and Blue Owl Capital, and Latham & Watkins has advised BridgeBio Pharma. HealthCare Royalty and Blue Owl Capital have acquired...
Immedica Pharma AB’s Acquisition of Marinus Pharmaceuticals
Gibson Dunn & Crutcher is advising Immedica Pharma AB on the transaction and Hogan Lovells is advising Marinus Pharmaceuticals, Inc. Immedica Pharma AB (Immedica), a leading...
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
Spyre Therapeutics’ $200 Million Common Stock Offering
Gibson Dunn & Crutcher advised Spyre Therapeutics, Inc. on the offering, and Covington & Burling advised the underwriters. Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:...
89bio Inc.’s $125 Million Common Stock Offering
Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters. 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the...
Jade Biosciences’ Merger with Aerovate Therapeutics
Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
GlycoMimetics’ Acquisition of Crescent Biopharma
Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
Inhibikase Therapeutics’ $110 Million Private Placement
Gibson, Dunn & Crutcher advised Fairmount Funds on the deal. Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company, announced the pricing...
Arrowhead Pharmaceuticals’ Financing Agreement with Sixth Street
Gibson, Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Rose advised Sixth Street. Arrowhead...